The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
Hogue, PharmD, FAPhA, FNAP, FFIP, executive vice president and CEO of APhA, commended the Federal Trade Commission's (FTC) action today against alleged practices by large vertically integrated ...